17:09 , Sep 29, 2017 |  BioCentury  |  Strategy

Agios’ acceleration

A biomarker-driven strategy in a setting where response was easy to measure, along with a healthy pile of cash, allowed Agios Pharmaceuticals Inc. to go from concept to marketed drug in just over eight years....
21:23 , Apr 6, 2017 |  BC Extra  |  Clinical News

Paper: IDH mutations sensitize cells to PARP inhibition

Researchers at Yale University School of Medicine are planning an NCI-sponsored clinical trial to test their hypothesis that cancer patients with isocitrate dehydrogenase 1 (IDH1) and IDH2 mutations will have better outcomes if treated with...
19:56 , Mar 14, 2017 |  BC Week In Review  |  Clinical News

DS-1001: Ph I started

Daiichi began a Japanese Phase I trial to evaluate oral DS-1001 in 60 patients. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan  Product: DS-1001  Business: Cancer  Molecular target: Isocitrate dehydrogenase 1 (IDH1)  Description: IDH1 inhibitor  Indication: Treat recurrent IDH1-mutant glioma  Endpoint: Dose-limiting toxicities...
07:00 , Aug 7, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Imaging

Approach Summary Licensing status Publication and contact information Imaging Intraoperative identification of isocitrate dehydrogenase 1 (IDH1)-mutant brain tumors via rapid mass spectrometric detection of 2-hydroxyglutarate (2-HG) A method...
07:00 , Apr 11, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute myelogenous leukemia (AML) Isocitrate dehydrogenase 2 (IDH2) Patient sample and in...
07:00 , Apr 11, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Isocitrate dehydrogenase 1 (IDH1) Mouse and in vitro studies suggest...
07:00 , Apr 11, 2013 |  BC Innovations  |  Targets & Mechanisms

Oncometabolite takedown

Agios Pharmaceuticals Inc. has reported the first mutant-selective inhibitors of the metabolic enzymes IDH1 and IDH2 and has shown that the molecules have a therapeutic effect in preclinical cancer models.1,2 The company also announced a...
08:00 , Mar 7, 2013 |  BC Innovations  |  Cover Story

Assaying 2-HG's function

Although 2-hydroxyglutarate is a known marker for various cancers, including leukemia,1,2 the metabolite's role in the disease remained unclear. Now, U.S. researchers have shown that the compound itself can drive leukemic transformation and that blocking...
08:00 , Feb 28, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Leukemia 2-Hydroxyglutarate (2-HG); isocitrate dehydrogenase 1 (IDH1) Cell culture studies suggest inhibiting the (R)-enantiomer of 2-HG could...
07:00 , Nov 1, 2012 |  BC Innovations  |  Cover Story

Revving up glycolysis

A trio of papers has provided new hints into how best to use small molecule activators of pyruvate kinase M2 isozyme, a cancer metabolism enzyme present nearly universally across tumor types. Based on that research,...